<?xml version="1.0" ?>
<document id="03ca47766e6f3e8d5d71fa25d86803f82d690b38">
  <chunk id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c0" text="Myricitrin Protects Cardiomyocytes from Hypoxia/Reoxygenation Injury: Involvement of Heat Shock Protein 90">
    <entity charOffset="0-10" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c0.e0" ontology_id="CHEBI_70082" text="Myricitrin" type="chemical"/>
    <entity charOffset="96-103" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c0.e1" ontology_id="CHEBI_16541" text="Protein" type="chemical"/>
  </chunk>
  <chunk id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1" text="Modulation of oxidative stress is therapeutically effective in ischemia/reperfusion (I/R) injury. Myricitrin, a naturally occurring phenolic compound, is a potent antioxidant. However, little is known about its effect on I/R injury to cardiac myocytes. The present study was performed to investigate the potential protective effect of myricitrin against hypoxia/reoxygenation (H/R)-induced H9c2 cardiomyocyte injury and its underlying mechanisms. Myricitrin pretreatment improved cardiomyocyte viability, inhibited ROS generation, maintained the mitochondrial membrane potential, reduced apoptotic cardiomyocytes, decreased the caspase-3 activity, upregulated antiapoptotic proteins and downregulated proapoptotic proteins during H/R injury. Moreover, the potential targets of myricitrin was predicted using Discovery Studio software, and heat shock protein 90 (Hsp90) was identified as the main disease-related target. Further mechanistic investigation revealed that 17-AAG, a pharmacologic inhibitor of Hsp90, significantly blocked the myricitrin-induced cardioprotective effect demonstrated by increased apoptosis and ROS generation. These results suggested that myricitrin provides protection to H9c2 cardiomyocytes against H/R-induced oxidative stress and apoptosis, most likely via increased expression of Hsp90.">
    <entity charOffset="98-108" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e0" ontology_id="CHEBI_70082" text="Myricitrin" type="chemical"/>
    <entity charOffset="335-345" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e1" ontology_id="CHEBI_70082" text="myricitrin" type="chemical"/>
    <entity charOffset="447-457" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e2" ontology_id="CHEBI_70082" text="Myricitrin" type="chemical"/>
    <entity charOffset="515-518" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e3" ontology_id="CHEBI_26523" text="ROS" type="chemical"/>
    <entity charOffset="674-682" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e4" ontology_id="CHEBI_36080" text="proteins" type="chemical"/>
    <entity charOffset="714-722" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e5" ontology_id="CHEBI_36080" text="proteins" type="chemical"/>
    <entity charOffset="777-787" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e6" ontology_id="CHEBI_70082" text="myricitrin" type="chemical"/>
    <entity charOffset="850-857" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e7" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="992-1001" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e8" ontology_id="CHEBI_35222" text="inhibitor" type="chemical"/>
    <entity charOffset="1121-1124" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e9" ontology_id="CHEBI_26523" text="ROS" type="chemical"/>
    <entity charOffset="1166-1176" id="03ca47766e6f3e8d5d71fa25d86803f82d690b38.c1.e10" ontology_id="CHEBI_70082" text="myricitrin" type="chemical"/>
  </chunk>
</document>
